About Sunshine Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.sunshinebiopharma.com/
Frequently Asked Questions
What is the 52-week range for SBFM?
The 52-week high is $24.3 and the 52-week low is $0.6715.
What is the P/E ratio for SBFM?
The P/E ratio data is currently unavailable.
What is the dividend yield for SBFM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -24.23%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -16.50%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.26.
Analyst Recommendation Trends
Wall Street analyst consensus for SBFM over the last few months:
Latest SBFM News
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions (NASDAQ:INBS)
Sunshine Biopharma Amends Articles Of Incorporation To Allow For Reverse Stock Split Of Up To 1-For-20; Board Of Directors Has Discretion To Effect The Split
On September 15, 2026, the Company received written consent in lieu of a meeting of stockholders from Dr. Steve N. Slilaty, our Chief Executive Officer, the holder of approximately 97% of the total voting power of the
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know
Sunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
* Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery * Global ondansetron market projected to reach $2. Ondansetron is the generic equivalent of the brand name, Zofran®.
Sunshine Biopharma Launches Generic Ondansetron Tablets Of 4mg And 8mg In Canadian Market
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgeryGlobal ondansetron market projected to reach $2.98 billion by 2034, up from $1.82
Sunshine Biopharma Says CEO Steve Slilaty, Holder Of About 97% Of Voting Power, Approved Reverse Stock Split Of Up To 1-For-20 By Written Consent
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001402328/000168316826007193/sunshine_8k.htmhttps://www.sec.gov/Archives/edgar/data/1402328/000168316826007195/sunshine_pre14c.htm
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 (J. 2024, 67, 13681−13702) and more recently in March 2026 (J.
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies. The company had previously published laboratory results on its library of compounds in August 2024 and more recently in March 2026. Background and Compound Research The company said that the nominated drug candidate for advanced development displayed nanomolar potency against the viral protease and had broad-spectrum activity against other SARS-CoV-2 variants of
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-07 | NATAN DAVID | +58,300 | - | - |
| 2026-04-14 | NATAN DAVID | +100,000 | - | - |